Gepotidacin is an oral, first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by blocking 2 different type II topoisomerase enzymes.
Fact checked by Nick Blackmer The Food and Drug Administration (FDA) recently approved a new antibiotic to treat urinary ...
The approval of gepotidacin (Blujepa; GSK) introduces the first new class of oral antibiotics for uncomplicated urinary tract ...
The Food and Drug Administration has approved a new antibiotic that can treat uncomplicated urinary tract infections, or ...
Blujepa, the first new oral UTI antibiotic in 30 years, offers hope against antibiotic-resistant infections, improving ...
The FDA approved GSK’s drug for a common type of urinary tract infection (UTI) in women and adolescent girls, one of five new ...
This antibiotic is the first new FDA-approved medication for urinary tract infections in decades, and meets the need for new ...
The US Food and Drug Administration has approved a new type of antibiotic to treat urinary tract infections. The pill, ...
On March 25, the U.S. Food and Drug Administration (FDA) approved the first new antibiotic to treat UTIs in 30 years. The ...
The FDA has approved GSK’s gepotidacin (Blujepa) for treating uncomplicated urinary tract infections (uUTIs) in females aged ...
The FDA approved gepotidacin for the treatment of uncomplicated UTIs in women and adolescent girls aged 12 years or older, ...